Less than a year after entering into a collaboration focused on using artificial intelligence tools to improve the early detection of cancer, Roche and Medial EarlySign are taking their relationship to the next level.
MacroGenics has closed a phase 2 clinical trial of its anti-cancer antibody enoblituzumab after learning of seven deaths potentially associated with hemorrhagic events. The setback means two of MacroGenics’ three attacks on the protein B7-H3 have hit setbacks, but the biotech is forging ahead with the third candidate.
When Karen Akinsanya, Ph.D., met for an interview, there was a palpable sense of both relief and excitement. A week earlier, on June 28, the head of R&D for Schrödinger’s new therapeutics wing had notched a major win—a green light from the FDA to start clinical trials with the company’s lead asset.
Researchers have discovered that quelling star-shaped brain cells called astrocytes could fight the long-term effects of traumatic brain injury, pointing to a protein involved in the process that could serve as a potential therapeutic target.
Adverum Biotechnologies is slashing its workforce by nearly 40%, cutting 78 employees under a new restructuring plan that will funnel resources to ixo-vec, a wet age-related macular degeneration (AMD) treatment candidate.
Alector’s new approach to Alzheimer’s disease has ended the way of many of the old ideas for how to tackle the perennial problem. After going over data including phase 1 results, AbbVie has severed its ties to a potential Alzheimer’s immunotherapy—and the asset has vanished from Alector’s pipeline.
Dynacure is acknowledging its lead asset, DYN101, is no dynamite cure for myotubular and centronuclear myopathies, ending development of the drug to the dismay of families hoping for a breakthrough.
Brown fat is considered the good fat, because, unlike energy-storing white fat, it burns calories. So expanding brown fat tissue or boosting its activity holds therapeutic promise to treat obesity.
Legend Biotech has calculated one of its early-stage CAR-T treatments isn’t ready for showtime, scrapping phase 1 plans for a cell therapy that just six weeks ago was freed from a FDA hold.
Using its artificial intelligence programs, Insilico Medicine said it has identified more than a handful of previously untapped genomic targets that could provide avenues to new treatments for amyotrophic lateral sclerosis and potentially rescue patients from the neurodegenerative effects of the disease better known as ALS.